Related Experiment Video
Updated: Jun 8, 2026
06:10
Seizure Activity Induced by Electroshock in Drosophila Larvae
Published on: June 6, 2025
Transient "sicca syndrome" during phenobarbital treatment
D Marino1, A Malandrini, R Rocchi
1Department of Neurological, Behavioural and Neurosurgical Sciences, Section of Neurological Sciences, University of Siena, Italy.
Journal of the Neurological Sciences
|October 19, 2010
Summary
Phenobarbital, an epilepsy drug, may cause Sjogren-like symptoms. This case report suggests considering drug-induced disorders when patients on barbiturates develop these symptoms.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Phenobarbital remains a widely used antiepileptic drug despite the availability of newer alternatives.
- Epilepsy management often involves long-term pharmacotherapy with various antiepileptic drugs.
- Autoimmune disorders are known potential adverse effects of some antiepileptic medications.
Observation:
- A 59-year-old woman with focal seizures experienced Sjogren-like symptoms after 30 days of phenobarbital treatment.
- Her serum phenobarbital levels were within the normal range during the symptomatic period.
- The Sjogren-like symptoms resolved upon discontinuation of phenobarbital and initiation of oxcarbazepine therapy.
Findings:
- This case presents the first reported instance of Sjogren's syndrome (Sicca Syndrome) as a potential adverse effect of phenobarbital.
- The temporal association suggests a possible drug-induced autoimmune reaction.
- Normal serum drug levels did not preclude the development of this adverse event.
Implications:
- Clinicians should consider phenobarbital as a potential cause of Sjogren-like symptoms in patients treated with barbiturates.
- This finding expands the spectrum of known autoimmune side effects associated with antiepileptic drugs.
- Further investigation may be warranted to elucidate the mechanism of phenobarbital-induced autoimmunity.
Related Concept Videos
01:20Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
01:14CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...